Update in the Therapy of Advanced Neuroendocrine Tumors.

about

Update in the Therapy of Advanced Neuroendocrine Tumors.

Item

http://www.wikidata.org/entity/Q49970741

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Update in the Therapy of Advanced Neuroendocrine Tumors.

@en

Update in the Therapy of Advanced Neuroendocrine Tumors.

@nl

type

Item

label

Update in the Therapy of Advanced Neuroendocrine Tumors.

@en

Update in the Therapy of Advanced Neuroendocrine Tumors.

@nl

prefLabel

Update in the Therapy of Advanced Neuroendocrine Tumors.

@en

Update in the Therapy of Advanced Neuroendocrine Tumors.

@nl

P1476

Update in the Therapy of Advanced Neuroendocrine Tumors.

@en

P2093

David J Gross

http://www.w3.org/2001/XMLSchema#string

Inbal Uri

http://www.w3.org/2001/XMLSchema#string

Shani Avniel-Polak

http://www.w3.org/2001/XMLSchema#string

Simona Grozinsky-Glasberg

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting the mTOR signaling pathway in neuroendocrine tumors

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

WOMEN IN CANCER THEMATIC REVIEW: Systemic therapies in neuroendocrine tumors and novel approaches toward personalized medicine

Lanreotide in metastatic enteropancreatic neuroendocrine tumors

The carcinoid syndrome: palliation by hepatic artery embolization

Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

P2888

s11864-017-0514-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-017-0514-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092708488

http://www.w3.org/2001/XMLSchema#string

P698

29143892

http://www.w3.org/2001/XMLSchema#string